Scios Nova announced on May 2, 1995, that a preliminary analysis of its Phase III clinical study of Auriculin
(anaritide) for the treatment of acute renal (kidney) failure (ARF) revealed that Auriculin
did not reduce the need for dialysis in the broad patient population, nor did the drug reduce mortality, though it did reduce the need for dialysis in a prospectively defined subgroup.
NYSE: GNE) today announced that they have entered into a collaboration agreement for the development of Scios Nova's Auriculin (R) anaritide for the treatment of acute renal (kidney) failure (ARF), which is currently in Phase III clinical trials.
Under the terms of the agreement, Genentech and Scios Nova will collaborate in the development of Auriculin for ARF in the United States and Canada.
In the rapidly changing healthcare environment, we believe that a partnership with Genentech will help ensure the successful launch of Auriculin and accelerate the market penetration in North America.
Genentech will also pay Scios Nova $50 million in milestone payments upon achievement of key development events and commercial targets, including $30 million upon Food and Drug Administration (FDA) marketing approval of Auriculin.
Auriculin has been designated an orphan drug for the treatment of ARF.